Increases in HDL-C were observed for all subgroups except two (subjects receiving atorvastatin 10 mg and 20 mg with systolic blood pressure <130 mm Hg [diastolic <85 mm Hg], n = 11 and 21, respectively) and most changes were nominally significant.
← all excerpts
Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk.
1
—
—